DDInter1042 DDInter1821
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Tizanidine {u} (Compound) resembles {v} (Compound) Brimonidine
Tizanidine {u} (Compound) binds {v} (Gene) CYP1A2
Tizanidine {u} (Compound) upregulates {v} (Gene) CDK6
Tizanidine {u} (Compound) palliates {v} (Disease) multiple sclerosis
Tizanidine {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Tizanidine {u} (Compound) downregulates {v} (Gene) USP22
Tizanidine {u} (Compound) causes {v} (Side Effect) Autonomic nervous system imbalance
Tizanidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Tizanidine (Compound) resembles Brimonidine (Compound)
Tizanidine (Compound) binds CYP1A2 (Gene)
Tizanidine (Compound) upregulates CDK6 (Gene)
Tizanidine (Compound) palliates multiple sclerosis (Disease)
Tizanidine (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Tizanidine (Compound) downregulates USP22 (Gene)
Tizanidine (Compound) causes Autonomic nervous system imbalance (Side Effect)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a